Skip to main content
Erschienen in: CME 9/2023

11.09.2023 | Spondylitis ankylosans | CME Fortbildung

Spondylitis ankylosans (Morbus Bechterew)

Ein aktueller Überblick

verfasst von: Prof. Dr. med. Herbert Kellner, Maria L. Voulgari

Erschienen in: CME | Ausgabe 9/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Spondylitis ankylosans (Morbus Bechterew) ist eine entzündlich rheumatische Erkrankung, die vorwiegend die Wirbelsäule betrifft. Die Symptome umfassen entzündlichen Rückenschmerz und Ankylose. Die Erkrankung ist auch mit Manifestationen wie Enthesitis (Sehnenansatzentzündung), Uveitis und selten mit Beteiligung anderer Organsysteme verbunden. HLA-B27 (genetisch determinierte Antigenvariante des Human Leukocyte Antigen-B) ist bei über 90% der Patientinnen und Patienten vorhanden, hat jedoch keinen diagnostischen Wert. Bildgebungsmethoden wie Röntgen und MRT sind entscheidend für die Diagnose von Spondylitis ankylosans (AS) und anderen Spondyloarthritiden. Die ASAS(Assessment of SpondyloArthritis international Society)-Klassifikationskriterien werden häufig zur Diagnosestellung herangezogen. Die Krankheitsaktivität bei ankylosierender Spondylitis wird neben dem klinischen Befund, der Bildgebung und der Labordiagnostik mithilfe von Indizes erfasst. Die Therapie umfasst Aufklärung, physikalische Therapie, NSAR, Biologika und ggf. operative Eingriffe.
Literatur
1.
Zurück zum Zitat U. Kiltz et al., "Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019," Zeitschrift für Rheumatol. 2019 781, vol. 78, no. 1, pp. 3-64, Nov. 2019, doi: 10.1007/S00393-019-0670-3. U. Kiltz et al., "Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019," Zeitschrift für Rheumatol. 2019 781, vol. 78, no. 1, pp. 3-64, Nov. 2019, doi: 10.1007/S00393-019-0670-3.
2.
Zurück zum Zitat J. A. Smith, E. Märker-Hermann, and R. A. Colbert, "Pathogenesis of ankylosing spondylitis: Current concepts," Best Pract. Res. Clin. Rheumatol., vol. 20, no. 3, pp. 571-591, Jun. 2006, doi: 10.1016/J.BERH.2006.03.001. J. A. Smith, E. Märker-Hermann, and R. A. Colbert, "Pathogenesis of ankylosing spondylitis: Current concepts," Best Pract. Res. Clin. Rheumatol., vol. 20, no. 3, pp. 571-591, Jun. 2006, doi: 10.1016/J.BERH.2006.03.001.
3.
Zurück zum Zitat J. D. Reveille et al., "Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci," Nat. Genet., vol. 42, no. 2, p. 123, Feb. 2010, doi: 10.1038/NG.513. J. D. Reveille et al., "Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci," Nat. Genet., vol. 42, no. 2, p. 123, Feb. 2010, doi: 10.1038/NG.513.
4.
Zurück zum Zitat D. Mauro, A. Nakamura, N. Haroon, and F. Ciccia, "The gut-enthesis axis and the pathogenesis of Spondyloarthritis," Semin. Immunol., vol. 58, Dec. 2021, doi: 10.1016/J.SMIM.2022.101607. D. Mauro, A. Nakamura, N. Haroon, and F. Ciccia, "The gut-enthesis axis and the pathogenesis of Spondyloarthritis," Semin. Immunol., vol. 58, Dec. 2021, doi: 10.1016/J.SMIM.2022.101607.
5.
Zurück zum Zitat J. A. Smith and R. A. Colbert, "The IL-23/IL-17 Axis in Spondyloarthritis Pathogenesis: Th17 and Beyond," Arthritis Rheumatol. (Hoboken, N.J.), vol. 66, no. 2, p. 231, 2014, doi: 10.1002/ART.38291. J. A. Smith and R. A. Colbert, "The IL-23/IL-17 Axis in Spondyloarthritis Pathogenesis: Th17 and Beyond," Arthritis Rheumatol. (Hoboken, N.J.), vol. 66, no. 2, p. 231, 2014, doi: 10.1002/ART.38291.
6.
Zurück zum Zitat A. Calin, J. Porta, J. F. Fries, and D. J. Schurman, "Clinical History as a Screening Test for Ankylosing Spondylitis," JAMA, vol. 237, no. 24, pp. 2613-2614, Jun. 1977, doi: 10.1001/JAMA.1977.03270510035017. A. Calin, J. Porta, J. F. Fries, and D. J. Schurman, "Clinical History as a Screening Test for Ankylosing Spondylitis," JAMA, vol. 237, no. 24, pp. 2613-2614, Jun. 1977, doi: 10.1001/JAMA.1977.03270510035017.
7.
Zurück zum Zitat M. Rudwaleit, A. Metter, J. Listing, J. Sieper, and J. Braun, "Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteria," Arthritis Rheum., vol. 54, no. 2, pp. 569-578, Feb. 2006, doi: 10.1002/ART.21619. M. Rudwaleit, A. Metter, J. Listing, J. Sieper, and J. Braun, "Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteria," Arthritis Rheum., vol. 54, no. 2, pp. 569-578, Feb. 2006, doi: 10.1002/ART.21619.
8.
Zurück zum Zitat J. Sieper et al., "New criteria for inflammatory back pain in patients with chronic back pain: A real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)," Ann. Rheum. Dis., vol. 68, no. 6, pp. 784-788, Jun. 2009, doi: 10.1136/ARD.2008.101501. J. Sieper et al., "New criteria for inflammatory back pain in patients with chronic back pain: A real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)," Ann. Rheum. Dis., vol. 68, no. 6, pp. 784-788, Jun. 2009, doi: 10.1136/ARD.2008.101501.
9.
Zurück zum Zitat S. M. Sharma and D. Jackson, "Uveitis and spondyloarthropathies," Best Pract. Res. Clin. Rheumatol., vol. 31, no. 6, pp. 846-862, Dec. 2017, doi: 10.1016/J.BERH.2018.08.002. S. M. Sharma and D. Jackson, "Uveitis and spondyloarthropathies," Best Pract. Res. Clin. Rheumatol., vol. 31, no. 6, pp. 846-862, Dec. 2017, doi: 10.1016/J.BERH.2018.08.002.
10.
Zurück zum Zitat C. Stolwijk, A. Van Tubergen, J. D. Castillo-Ortiz, and A. Boonen, "Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-analysis," Ann. Rheum. Dis., vol. 74, no. 1, pp. 65-73, Jan. 2015, doi: 10.1136/ANNRHEUMDIS-2013-203582/-/DC1. C. Stolwijk, A. Van Tubergen, J. D. Castillo-Ortiz, and A. Boonen, "Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-analysis," Ann. Rheum. Dis., vol. 74, no. 1, pp. 65-73, Jan. 2015, doi: 10.1136/ANNRHEUMDIS-2013-203582/-/DC1.
11.
Zurück zum Zitat T. R. Jenkinson, P. A. Mallorie, H. C. Whitelock, L. G. Kennedy, S. L. Garrett, and A. Calin, "Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.," J. Rheumatol., vol. 21, no. 9, pp. 1694-1698, Sep. 1994, Accessed: Mar. 27, 2023. [Online]. Available: https://europepmc.org/article/med/7799351. T. R. Jenkinson, P. A. Mallorie, H. C. Whitelock, L. G. Kennedy, S. L. Garrett, and A. Calin, "Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.," J. Rheumatol., vol. 21, no. 9, pp. 1694-1698, Sep. 1994, Accessed: Mar. 27, 2023. [Online]. Available: https://​europepmc.​org/​article/​med/​7799351.
12.
Zurück zum Zitat M. Rudwaleit et al., "The early disease stage in axial spondylarthritis: Results from the German spondyloarthritis inception cohort," Arthritis Rheum., vol. 60, no. 3, pp. 717-727, Mar. 2009, doi: 10.1002/ART.24483. M. Rudwaleit et al., "The early disease stage in axial spondylarthritis: Results from the German spondyloarthritis inception cohort," Arthritis Rheum., vol. 60, no. 3, pp. 717-727, Mar. 2009, doi: 10.1002/ART.24483.
13.
Zurück zum Zitat A. Chatzikyriakidou, P. V. Voulgari, and A. A. Drosos, "What is the role of HLA-B27 in spondyloarthropathies?," Autoimmun. Rev., vol. 10, no. 8, pp. 464-468, Jun. 2011, doi: 10.1016/J.AUTREV.2011.01.011. A. Chatzikyriakidou, P. V. Voulgari, and A. A. Drosos, "What is the role of HLA-B27 in spondyloarthropathies?," Autoimmun. Rev., vol. 10, no. 8, pp. 464-468, Jun. 2011, doi: 10.1016/J.AUTREV.2011.01.011.
14.
Zurück zum Zitat P. Mandl et al., "EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice," Ann. Rheum. Dis., vol. 74, no. 7, pp. 1327-1339, Jul. 2015, doi: 10.1136/ANNRHEUMDIS-2014-206971. P. Mandl et al., "EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice," Ann. Rheum. Dis., vol. 74, no. 7, pp. 1327-1339, Jul. 2015, doi: 10.1136/ANNRHEUMDIS-2014-206971.
15.
Zurück zum Zitat S. Van Der Linden, H. A. Valkenburg, and A. Cats, "Evaluation of Diagnostic Criteria for Ankylosing Spondylitis," Arthritis Rheum., vol. 27, no. 4, pp. 361-368, Apr. 1984, doi: 10.1002/ART.1780270401. S. Van Der Linden, H. A. Valkenburg, and A. Cats, "Evaluation of Diagnostic Criteria for Ankylosing Spondylitis," Arthritis Rheum., vol. 27, no. 4, pp. 361-368, Apr. 1984, doi: 10.1002/ART.1780270401.
16.
Zurück zum Zitat D. Van Der Heijde et al., "Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis," Rheumatology, vol. 58, no. 3, pp. 388-400, Mar. 2019, doi: 10.1093/RHEUMATOLOGY/KEY128. D. Van Der Heijde et al., "Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis," Rheumatology, vol. 58, no. 3, pp. 388-400, Mar. 2019, doi: 10.1093/RHEUMATOLOGY/KEY128.
17.
Zurück zum Zitat M. Rudwaleit et al., "Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group.," Ann. Rheum. Dis., vol. 68, no. 10, pp. 1520-1527, May 2009, doi: 10.1136/ARD.2009.110767. M. Rudwaleit et al., "Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group.," Ann. Rheum. Dis., vol. 68, no. 10, pp. 1520-1527, May 2009, doi: 10.1136/ARD.2009.110767.
18.
Zurück zum Zitat K. G. A. Hermann et al., "Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group," Ann. Rheum. Dis., vol. 71, no. 8, pp. 1278-1288, Aug. 2012, doi: 10.1136/ARD.2011.150680. K. G. A. Hermann et al., "Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group," Ann. Rheum. Dis., vol. 71, no. 8, pp. 1278-1288, Aug. 2012, doi: 10.1136/ARD.2011.150680.
19.
Zurück zum Zitat M. Rudwaleit et al., "The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal," Ann. Rheum. Dis., vol. 68, no. 6, pp. 770-776, Jun. 2009, doi: 10.1136/ARD.2009.108217. M. Rudwaleit et al., "The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal," Ann. Rheum. Dis., vol. 68, no. 6, pp. 770-776, Jun. 2009, doi: 10.1136/ARD.2009.108217.
20.
Zurück zum Zitat E. Feldtkeller, M. A. Khan, D. Van Der Heijde, S. Van Der Linden, and J. Braun, "Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis," Rheumatol. Int., vol. 23, no. 2, pp. 61-66, 2003, doi: 10.1007/S00296-002-0237-4/METRICS. E. Feldtkeller, M. A. Khan, D. Van Der Heijde, S. Van Der Linden, and J. Braun, "Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis," Rheumatol. Int., vol. 23, no. 2, pp. 61-66, 2003, doi: 10.1007/S00296-002-0237-4/METRICS.
21.
Zurück zum Zitat J. Brandt et al., "[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].," Z. Rheumatol., vol. 62, no. 3, pp. 264-273, Jun. 2003, doi: 10.1007/S00393-003-0522-Y. J. Brandt et al., "[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].," Z. Rheumatol., vol. 62, no. 3, pp. 264-273, Jun. 2003, doi: 10.1007/S00393-003-0522-Y.
22.
Zurück zum Zitat J. Ruof, O. Sangha, and G. Stucki, "Evaluation einer deutschen version des Bath Ankylosing Spondylitis Functional Index (BASFI) und Dougados Functional Index (D-FI)," Z. Rheumatol., vol. 58, no. 4, pp. 218-225, 1999, doi: 10.1007/S003930050174/METRICS. J. Ruof, O. Sangha, and G. Stucki, "Evaluation einer deutschen version des Bath Ankylosing Spondylitis Functional Index (BASFI) und Dougados Functional Index (D-FI)," Z. Rheumatol., vol. 58, no. 4, pp. 218-225, 1999, doi: 10.1007/S003930050174/METRICS.
23.
Zurück zum Zitat P. MacHado et al., "Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores," Ann. Rheum. Dis., vol. 70, no. 1, pp. 47-53, Jan. 2011, doi: 10.1136/ARD.2010.138594. P. MacHado et al., "Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores," Ann. Rheum. Dis., vol. 70, no. 1, pp. 47-53, Jan. 2011, doi: 10.1136/ARD.2010.138594.
24.
Zurück zum Zitat S. Ramiro et al., "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update," Ann. Rheum. Dis., vol. 82, no. 1, pp. 19-34, Jan. 2023, doi: 10.1136/ARD-2022-223296. S. Ramiro et al., "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update," Ann. Rheum. Dis., vol. 82, no. 1, pp. 19-34, Jan. 2023, doi: 10.1136/ARD-2022-223296.
25.
Zurück zum Zitat H. Dagfinrud, T. K. Kvien, and K. B. Hagen, "Physiotherapy interventions for ankylosing spondylitis," Cochrane Database Syst. Rev., vol. 2008, no. 1, 2008, doi: 10.1002/14651858.CD002822.PUB3. H. Dagfinrud, T. K. Kvien, and K. B. Hagen, "Physiotherapy interventions for ankylosing spondylitis," Cochrane Database Syst. Rev., vol. 2008, no. 1, 2008, doi: 10.1002/14651858.CD002822.PUB3.
26.
Zurück zum Zitat F. P. B. Kroon et al., "Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review," J. Rheumatol., vol. 43, no. 3, pp. 607-617, Mar. 2016, doi: 10.3899/JRHEUM.150721. F. P. B. Kroon et al., "Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review," J. Rheumatol., vol. 43, no. 3, pp. 607-617, Mar. 2016, doi: 10.3899/JRHEUM.150721.
27.
Zurück zum Zitat J. R. Maneiro, A. Souto, E. Salgado, A. Mera, and J. J. Gomez-Reino, "Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis," RMD open, vol. 1, no. 1, Jan. 2015, doi: 10.1136/RMDOPEN-2014-000017. J. R. Maneiro, A. Souto, E. Salgado, A. Mera, and J. J. Gomez-Reino, "Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis," RMD open, vol. 1, no. 1, Jan. 2015, doi: 10.1136/RMDOPEN-2014-000017.
28.
Zurück zum Zitat J. Zochling, D. Van Der Heijde, M. Dougados, and J. Braun, "Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis," Ann. Rheum. Dis., vol. 65, no. 4, p. 423, Apr. 2006, doi: 10.1136/ARD.2005.041129. J. Zochling, D. Van Der Heijde, M. Dougados, and J. Braun, "Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis," Ann. Rheum. Dis., vol. 65, no. 4, p. 423, Apr. 2006, doi: 10.1136/ARD.2005.041129.
29.
Zurück zum Zitat J. Chen, S. Lin, and C. Liu, "Sulfasalazine for ankylosing spondylitis," Cochrane Database Syst. Rev., vol. 2014, no. 11, Nov. 2014, doi: 10.1002/14651858.CD004800.PUB3/MEDIA/CDSR/CD004800/IMAGE_N/NCD004800-CMP-003-08.PNG. J. Chen, S. Lin, and C. Liu, "Sulfasalazine for ankylosing spondylitis," Cochrane Database Syst. Rev., vol. 2014, no. 11, Nov. 2014, doi: 10.1002/14651858.CD004800.PUB3/MEDIA/CDSR/CD004800/IMAGE_N/NCD004800-CMP-003-08.PNG.
Metadaten
Titel
Spondylitis ankylosans (Morbus Bechterew)
Ein aktueller Überblick
verfasst von
Prof. Dr. med. Herbert Kellner
Maria L. Voulgari
Publikationsdatum
11.09.2023
Verlag
Springer Medizin
Erschienen in
CME / Ausgabe 9/2023
Print ISSN: 1614-371X
Elektronische ISSN: 1614-3744
DOI
https://doi.org/10.1007/s11298-023-3267-8

Weitere Artikel der Ausgabe 9/2023

CME 9/2023 Zur Ausgabe

Editorial

Editorial

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 49 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.